Article, big buy-outs in biotech. We knew about the huge price ARIA is fetching, but I didn't know that the Dendreon division of Valeant was sold for 819 million bucks. They have exactly one product, the prostate cancer incredibly expensive course of treatment with personalized immunotherapy.

http://www.fiercepharma.com/pharma-asia/fierc...oifQ%3D%3D

So if that non-standard treatment is worth 819 million, what would be the value of a treatment by a first-line drug for a more common disease, like psoriasis?
(rhetorical question)